NCT02342392View on ClinicalTrials.gov

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Pterygium
Interventions
DRUG

ranibizumab

Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.

All Listed Sponsors
lead

Universiti Sains Malaysia

OTHER

NCT02342392 - Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study | Biotech Hunter | Biotech Hunter